Cacabelos R - Search Results

1

Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease.

Cherif O, Allouche F, Chabchoub F, Chioua M, Soriano E, Yañez M, Cacabelos R, Romero A, López MG, Marco-Contelles J. Cherif O, et al. Among authors: cacabelos r. Future Med Chem. 2014;6(17):1883-91. doi: 10.4155/fmc.14.115. Future Med Chem. 2014. PMID: 25495982

2

Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer's disease.

Chioua M, Pérez M, Bautista-Aguilera OM, Yañez M, López MG, Romero A, Cacabelos R, de la Bellacasa RP, Brogi S, Butini S, Borrell JI, Marco-Contelles J. Chioua M, et al. Among authors: cacabelos r. Mini Rev Med Chem. 2015;15(8):648-58. doi: 10.2174/1389557515666150219130156. Mini Rev Med Chem. 2015. PMID: 25694076

3

Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease.

Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A, Marco-Contelles J. Romero A, et al. Among authors: cacabelos r. Bioorg Med Chem Lett. 2013 Apr 1;23(7):1916-22. doi: 10.1016/j.bmcl.2013.02.017. Epub 2013 Feb 16. Bioorg Med Chem Lett. 2013. PMID: 23481643 Free article. Review.

4

Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices.

Patiño P, Parada E, Farré-Alins V, Molz S, Cacabelos R, Marco-Contelles J, López MG, Tasca CI, Ramos E, Romero A, Egea J. Patiño P, et al. Among authors: cacabelos r. Neurotoxicology. 2016 Dec;57:61-68. doi: 10.1016/j.neuro.2016.09.002. Epub 2016 Sep 9. Neurotoxicology. 2016. PMID: 27620136

5

Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®).

Romero A, Parada E, González-Lafuente L, Farré-Alins V, Ramos E, Cacabelos R, Egea J. Romero A, et al. Among authors: cacabelos r. CNS Neurosci Ther. 2017 May;23(5):450-452. doi: 10.1111/cns.12693. Epub 2017 Mar 30. CNS Neurosci Ther. 2017. PMID: 28371323 Free PMC article. No abstract available.

6

Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease.

Aliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, Ashraf GM, Jabir NR, Kamal MA, Nikolenko VN, Zamyatnin AA Jr, Benberin VV, Bachurin SO. Aliev G, et al. Among authors: cacabelos r. Curr Med Chem. 2014;21(19):2208-17. doi: 10.2174/0929867321666131227161303. Curr Med Chem. 2014. PMID: 24372221 Review.

7

Pharmacogenomics in Alzheimer's disease.

Cacabelos R. Cacabelos R. Mini Rev Med Chem. 2002 Feb;2(1):59-84. doi: 10.2174/1389557023406458. Mini Rev Med Chem. 2002. PMID: 12369958 Review.

8

Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.

Cacabelos R, Llovo R, Fraile C, Fernández-Novoa L. Cacabelos R, et al. Curr Alzheimer Res. 2007 Sep;4(4):479-500. doi: 10.2174/156720507781788846. Curr Alzheimer Res. 2007. PMID: 17908053 Review.

9

Epigenetic drug discovery for Alzheimer's disease.

Cacabelos R, Torrellas C. Cacabelos R, et al. Expert Opin Drug Discov. 2014 Sep;9(9):1059-86. doi: 10.1517/17460441.2014.930124. Epub 2014 Jul 3. Expert Opin Drug Discov. 2014. PMID: 24989365 Review.

10

Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development.

Cacabelos R, Cacabelos P, Torrellas C, Tellado I, Carril JC. Cacabelos R, et al. Among authors: cacabelos p. Methods Mol Biol. 2014;1175:323-556. doi: 10.1007/978-1-4939-0956-8_13. Methods Mol Biol. 2014. PMID: 25150875 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

216 results

Search Page